Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants
Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants
Cocrystal Pharma計劃由於參與者中流感感染率低，延長口服PB2抑制劑CC-42344的第2a階段流感挑戰研究。
"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of the challenge influenza strain used in this study. The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules. The low infectivity obtained in this study hindered antiviral data analysis," said Sam Lee, Ph.D., Cocrystal's President and co-CEO.
"雖然CC-42344展現了良好的安全性和耐受性，但我們對本研究中使用的挑戰性流感毒株的低傳染率感到失望。建立健康、未感染研究對象的穩健流感感染對於判斷評估抗病毒分子的臨牀終點至關重要。本研究中獲得的低傳染性阻礙了抗病毒數據的分析，" Cocrystal的總裁兼聯席首席執行官Sam Lee博士說道。